Effects of cerivastatin in dyslipemia and other cardiovascular risk factors after renal transplantation
Garcia I., Errasti P., Lavilla F.J., Ballester B., Manrique J., Rossich E., Purroy A.
Renal Unit. University Clinic. University of Navarra. Pamplona (Spain)
Hyperlipidemia is a frequent complication observed in kidney transplant recipients (KTR). Its role as a major factor for the development of atherosclerosis and heart disease is well known. In spite of new immunosuppressive drugs and better management of infectious diseases, the incidence of death attributable to cardiovascular disease in KTR is higher than in the general population.
Risk factors for the development of vascular disease in KTR include diabetes, hypertension, hyperlipidemia, smoking, hyperfibrinogenemia, hyperhomocysteinemia, and immunosuppressive drugs. Hyperlipidemia also plays an important role in the development of chronic graft dysfunction, the leading cause of late graft loss.
The HMG-CoA reductase inhibitors (statins) are the most powerful drugs for lowering cholesterol in KTR. The aim of this study was to evaluate the effects of a new statin, cerivastatin (CV; Lipobay, Bayer) on dyslipemia and other vascular risk factors in KTR.
CITATION Transplant Proc. 2002 Feb;34(1):401-2